Disclaimer

We are currently suffering from haze, with Air Pollution Index (API) readings across the country remaining unhealthy as of today 😷 Let's take a look at this Phase 1 study attached, which demonstrated the safety and feasibility of intravenous autologous mesenchymal stromal cell (MSCs) administration in patients with severe emphysema. It showed no signs of fibrosis development in lung tissue 3–4 weeks after MSC infusion, nor in CT-derived parenchymal analysis at the 1-year follow-up.

Have you ever wondered if there are any promising interventions for idiopathic pulmonary fibrosis (IPF)? 🤔 Let's take a look at this study we've found. This clinical trial is demonstrating an acceptable safety profile for the endobronchial administration of autologous Adipose-derived Stromal Cells-Stromal Vascular Fraction (ADSCs-SVF) in patients with IPF, showing an ability to improve the patients' quality of life (as measured by the SGRQ). Most importantly, the pulmonary parameters do improve, even though the changes are not statistically significant. 

Here attached another summary of a 1b clinical study on placenta-derived MSCs in idiopathic pulmonary fibrosis (IPF), published in 2014. 📃 The results may not be statistically significant; however, this study provides the first evidence of the feasibility and short-term safety of delivering MSCs via the intravenous route to humans with significant fibrotic lung disease. It lays the foundation for future efficacy studies. 🔍

🤔 Key fact: Did you know that chronic obstructive pulmonary disease (COPD) is the third leading cause of death worldwide, resulting from chronic inflammation of the lungs?  According to the WHO, COPD caused 3.23 million deaths in 2019. 😢 Today, let's delve into a pilot clinical study on allogeneic umbilical cord MSC administration for COPD. In this study, the intervention appears to be safe in patients with moderate-to-severe COPD, significantly improves their quality of life, and thus provides a basis for subsequent cell therapy investigations.